RFK Jr. Just Announced 12 Peptides Are Coming Off the FDA's Banned List. We Read the Fine Print — Here's What Actually Changes for Australians.

ProtocolHub provides educational information only. All peptide and pharmaceutical therapies require consultation with an AHPRA-registered medical practitioner. Information on this site does not constitute medical advice. ProtocolHub may earn affiliate commissions from partner referrals — this does not affect our editorial recommendations.

The Kennedy announcement is real, the FDA federal notice is confirmed, and 12 peptides — including BPC-157, GHK-Cu injectable, Epitalon, and MOTS-c — are being removed from the FDA's most restrictive category. For Australian users of these compounds, this changes something, but not what most people think. The TGA operates independently of the FDA. Your access pathway in Australia has not changed today. Here is exactly what happened, what it means in the US, what it means here, and the two things Australians should actually watch.

What Kennedy announced — and what the FDA has confirmed

HHS Secretary Robert F. Kennedy Jr. posted today that the FDA will remove 12 peptides from Category 2 — the FDA's classification for compounds that "raise significant safety risks" and cannot be lawfully produced by compounding pharmacies. Kennedy's post states that nominators withdrew their submissions for these 12 compounds, triggering their removal, and that the FDA will bring them to the Pharmacy Compounding Advisory Committee (PCAC) for independent scientific review at its next two meetings, beginning in July.

The 12 peptides named in the announcement:

BPC-157 · Thymosin beta-4 fragment · Epitalon · GHK-Cu (injectable) · MOTS-c · DSIP (Emideltide) · Dihexa Acetate · Ibutamoren Mesylate · Melanotan II · KPV · Semax · Cathelicidin LL-37

This is confirmed. The FDA published a formal federal notice on April 15, 2026, stating it will ask a panel of outside advisers to review seven of these peptides — including BPC-157 and TB-500 — at the July PCAC meeting, specifically whether they should be removed from the Category 2 restricted list. ABC News and NBC News confirmed the notice independently.

The post also states the original restriction was applied in "September 2023" by the Biden FDA. Multiple sources confirm the Category 2 list was established across 2022–2023. The specific September 2023 framing refers to the period when enforcement was formalised — the broader restriction developed over that period.

What Category 2 actually meant in the US — and why it matters

The FDA's 503A framework governs what compounding pharmacies can and cannot legally prepare for individual patients. Category 2 was effectively a ban: these compounds could not be lawfully compounded regardless of a physician's prescription. The consequence was exactly what Kennedy describes — a black market. American patients who wanted BPC-157 or GHK-Cu injectable were forced into unregulated sources: research chemical suppliers, overseas grey-market vendors, and unlicensed compounders with no quality control.

Removing these compounds from Category 2 and sending them to PCAC for scientific review is the first step toward a legitimate US compounding pathway. If PCAC recommends favourably and the FDA acts on that recommendation through formal rulemaking, US compounding pharmacies will be able to legally prepare these compounds under physician prescription.

That process — PCAC review in July, followed by formal FDA rulemaking — is not overnight. Legal experts estimate several months to over a year before any formal rule change is published. The Kennedy post's claim that this will "immediately begin shifting demand away from the black market" is optimistic. The legal status in the US does not change until the FDA publishes a formal rule update. No formal rule has been published as of today.

One important note: Dr. Peter Lurie, former FDA official, told ABC News he has doubts about whether the PCAC review will be genuinely independent given Kennedy's stated position: "Everybody knows the outcome that the secretary wants." ProtocolHub is not in a position to assess the integrity of the PCAC process — we are noting the criticism exists from a credible source.

What this means for Australians — the direct answer

Your Australian access to these compounds has not changed today.

The TGA operates under its own regulatory framework — the Therapeutic Goods Act 1989 and associated scheduling decisions. TGA classifications are made independently of FDA decisions. The FDA placing BPC-157 on Category 2 in 2023 did not change Australian law. The FDA removing it from Category 2 in 2026 does not change Australian law.

In Australia, the peptides named in Kennedy's announcement are predominantly Schedule 4 compounds — meaning they require a prescription from an AHPRA-registered medical practitioner and must be sourced through a TGA-licensed compounding pharmacy. That pathway exists today and has existed throughout the period when these same compounds were banned in the US.

This is the part most Australian commentary will miss: Australians were never subject to the FDA's Category 2 ban. The access pathway for BPC-157, GHK-Cu injectable, Epitalon, and MOTS-c through Australian compounding pharmacies under an AHPRA prescription has been continuous. The chaos in the US did not apply here.

Find an AHPRA-registered Australian clinic for these peptides →

ProtocolHub earns a commission when you visit partner links. This does not affect our recommendations.

Two things Australians should actually watch

The Kennedy announcement matters for Australia in two indirect ways that are worth tracking.

1. Global supply quality is about to improve

The US Category 2 ban pushed American demand into grey-market suppliers. Those suppliers also served Australian clients. When US compounding pharmacies can legally operate again, professional-grade pharmaceutical compounders will re-enter the market at scale. The quality, sterility, and purity of compounds available globally — including those accessed by Australian patients — will improve as a consequence. This is not a regulatory change for Australia. It is a supply chain change with real safety implications.

2. The TGA watches international regulatory precedent

The TGA does not follow the FDA automatically, but it does monitor international regulatory developments as part of its evidence base. A US regulatory system moving toward evaluated, supervised access for compounds like BPC-157 and GHK-Cu injectable weakens the argument that these compounds are globally too risky for regulated access. It does not guarantee a TGA scheduling change — the TGA makes its own assessments — but it shifts the international regulatory context in a direction that historically correlates with TGA reviewing its own positions.

If PCAC recommends these compounds for compounding access and the FDA formalises that, the TGA will have US regulatory data to consider in any future review. That is a meaningful development for the Australian access landscape over a 2–5 year horizon.

What are these compounds and what are they used for in Australia?

A brief orientation for readers who have seen the list but are unfamiliar with every compound.

BPC-157 — Schedule 4 in Australia. Gut repair, tendon and ligament recovery. The most researched healing peptide on ProtocolHub with over 180 pre-clinical studies.

Thymosin beta-4 fragment (TB-500) — Schedule 4 in Australia. Systemic tissue repair, wound healing. Used in the Wolverine Recovery Stack alongside BPC-157.

Epitalon — Schedule 4 in Australia. Telomere maintenance, anti-ageing. Annual course protocol.

GHK-Cu (injectable) — Schedule 4 in Australia. Collagen synthesis, tissue remodelling, cellular regeneration. Used in Bryan Johnson's Blueprint protocol.

MOTS-c — Available via specialist compounding pharmacies in Australia. Mitochondrial function, metabolic health.

KPV — Anti-inflammatory peptide, gut health applications. Increasingly available via Australian compounders.

Semax — Neuroprotection, cognitive function. Available via specialist compounding in Australia.

Ibutamoren (MK-677) — Oral GH secretagogue. Available in Australia.

Melanotan II, DSIP, Dihexa, LL-37 — Various availability via Australian compounding pharmacies. Consult your AHPRA-registered practitioner for current access status.

The honest assessment of Kennedy's post

The post is accurate in its key claims: the nominations were withdrawn, the FDA has confirmed PCAC review in July, and the direction of travel is toward restored US compounding access for these compounds.

Where it overstates: "immediately begin shifting demand away from the black market" is premature. Until formal rulemaking is complete, the legal status in the US is unchanged. PCAC review is the beginning of a process, not the end of one.

Where it understates: the significance of PCAC review is higher than the post implies. If PCAC recommends favourably — which Kennedy's own involvement makes likely — the formal rulemaking process will follow with political backing. This is the most significant regulatory development for the US peptide compounding market since the original Category 2 restrictions were imposed.

For Australians: the access pathway was never blocked in the way it was in the US. The significance here is indirect — global supply quality, international regulatory precedent, and the legitimacy signal of a sitting HHS Secretary stating on record that these compounds belong in a regulated medical framework.

---

ProtocolHub provides educational information only. All peptide and pharmaceutical therapies require consultation with an AHPRA-registered medical practitioner. Information on this site does not constitute medical advice.

What to read next

• BPC-157 peptide profile — Australian access, evidence, and prescribing pathway
• GHK-Cu peptide profile — mechanism, evidence, and Australian compounding access
• Epithalon peptide profile — telomere maintenance and annual cycle guidance
• Peptides in Australia — the complete legal guide — TGA scheduling explained for every major compound
• The Recovery & Repair Stack — BPC-157 and TB-500 Australian protocol
• Compare Australian peptide clinics